Intensity Therapeutics, Inc. (INTS) stock
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$3.07−0.01 (-0.32%)
Close on Nov 16, 2026Market cap $10.02MP/E –Yield –
Intensity Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Intensity Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$11.48M. For fiscal 2025 it was -$11.97M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.97M | – |
| FY2024 | Dec 31, 2024 | -$16.59M | – |
| FY2023 | Dec 31, 2023 | -$8.32M | – |
| FY2022 | Dec 31, 2022 | -$7.55M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.53M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.14M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.07M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.35M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.77M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.93M | – |
See a number that looks wrong?